Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-10-12

AUTHORS

R Fleischmann, P J Mease, S Schwartzman, L-J Hwang, K Soma, C A Connell, L Takiya, E Bananis

ABSTRACT

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis investigated the effect of methotrexate (MTX) dose on the efficacy of tofacitinib in patients with RA. ORAL Scan (NCT00847613) was a 2-year, randomized, Phase 3 trial evaluating tofacitinib in MTX-inadequate responder (IR) patients with RA. Patients received tofacitinib 5 or 10 mg twice daily (BID), or placebo, with low (≤12.5 mg/week), moderate (>12.5 to <17.5 mg/week), or high (≥17.5 mg/week) stable background MTX. Efficacy endpoints (at months 3 and 6) included American College of Rheumatology (ACR) 20/50/70 response rates, and mean change from baseline in Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 joints (DAS28)-4(erythrocyte sedimentation rate [ESR]), Health Assessment Questionnaire-Disability Index (HAQ-DI), and modified Total Sharp score. 797 patients were treated with tofacitinib 5 mg BID (N = 321), tofacitinib 10 mg BID (N = 316), or placebo (N = 160); 242, 333, and 222 patients received low, moderate, and high MTX doses, respectively. At months 3 and 6, ACR20/50/70 response rates were greater for both tofacitinib doses vs placebo across all MTX doses. At month 3, mean changes from baseline in CDAI and HAQ-DI were significantly greater for both tofacitinib doses vs placebo, irrespective of MTX category; improvements were maintained at month 6. Both tofacitinib doses demonstrated improvements in DAS28-4(ESR), and less structural progression vs placebo, across MTX doses at month 6. Tofacitinib plus MTX showed greater clinical and radiographic efficacy than placebo in MTX-IR patients with RA, regardless of MTX dose. More... »

PAGES

15-24

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10067-016-3436-1

DOI

http://dx.doi.org/10.1007/s10067-016-3436-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1011836710

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27734232


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arthritis, Rheumatoid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Sedimentation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Janus Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methotrexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrroles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Regression Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA.", 
          "id": "http://www.grid.ac/institutes/grid.267313.2", 
          "name": [
            "Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fleischmann", 
        "givenName": "R", 
        "id": "sg:person.01065106031.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065106031.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA.", 
          "id": "http://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mease", 
        "givenName": "P J", 
        "id": "sg:person.012234527537.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012234527537.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital for Special Surgery, New York, NY, USA.", 
          "id": "http://www.grid.ac/institutes/grid.239915.5", 
          "name": [
            "Hospital for Special Surgery, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartzman", 
        "givenName": "S", 
        "id": "sg:person.014133305773.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, New York, NY, USA.", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hwang", 
        "givenName": "L-J", 
        "id": "sg:person.01323573350.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323573350.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Groton, CT, USA.", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Groton, CT, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Soma", 
        "givenName": "K", 
        "id": "sg:person.01011713026.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011713026.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Groton, CT, USA.", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Groton, CT, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Connell", 
        "givenName": "C A", 
        "id": "sg:person.0614545245.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614545245.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Collegeville, PA, USA.", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Collegeville, PA, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takiya", 
        "givenName": "L", 
        "id": "sg:person.011262137261.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011262137261.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Collegeville, PA, USA. stratis.bananis@pfizer.com.", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Collegeville, PA, USA. stratis.bananis@pfizer.com."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bananis", 
        "givenName": "E", 
        "id": "sg:person.01073167753.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073167753.60"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2016-10-12", 
    "datePublishedReg": "2016-10-12", 
    "description": "Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis investigated the effect of methotrexate (MTX) dose on the efficacy of tofacitinib in patients with RA. ORAL Scan (NCT00847613) was a 2-year, randomized, Phase 3 trial evaluating tofacitinib in MTX-inadequate responder (IR) patients with RA. Patients received tofacitinib 5 or 10\u00a0mg twice daily (BID), or placebo, with low (\u226412.5\u00a0mg/week), moderate (>12.5 to <17.5\u00a0mg/week), or high (\u226517.5\u00a0mg/week) stable background MTX. Efficacy endpoints (at months 3 and 6) included American College of Rheumatology (ACR) 20/50/70 response rates, and mean change from baseline in Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 joints (DAS28)-4(erythrocyte sedimentation rate [ESR]), Health Assessment Questionnaire-Disability Index (HAQ-DI), and modified Total Sharp score. 797 patients were treated with tofacitinib 5\u00a0mg BID (N\u00a0=\u00a0321), tofacitinib 10\u00a0mg BID (N\u00a0=\u00a0316), or placebo (N\u00a0=\u00a0160); 242, 333, and 222 patients received low, moderate, and high MTX doses, respectively. At months 3 and 6, ACR20/50/70 response rates were greater for both tofacitinib doses vs placebo across all MTX doses. At month 3, mean changes from baseline in CDAI and HAQ-DI were significantly greater for both tofacitinib doses vs placebo, irrespective of MTX category; improvements were maintained at month 6. Both tofacitinib doses demonstrated improvements in DAS28-4(ESR), and less structural progression vs placebo, across MTX doses at month 6. Tofacitinib plus MTX showed greater clinical and radiographic efficacy than placebo in MTX-IR patients with RA, regardless of MTX dose.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10067-016-3436-1", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1093299", 
        "issn": [
          "0770-3198", 
          "1434-9949"
        ], 
        "name": "Clinical Rheumatology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "keywords": [
      "Health Assessment Questionnaire Disability Index", 
      "Clinical Disease Activity Index", 
      "efficacy of tofacitinib", 
      "rheumatoid arthritis", 
      "MTX doses", 
      "tofacitinib 5", 
      "month 3", 
      "month 6", 
      "response rate", 
      "MTX-inadequate responder patients", 
      "Rheumatology (ACR) 20/50/70 response rates", 
      "oral Janus kinase inhibitor", 
      "higher MTX doses", 
      "ACR20/50/70 response rates", 
      "MTX-IR patients", 
      "Disease Activity Index", 
      "Disease Activity Score", 
      "phase 3 trial", 
      "total Sharp score", 
      "Janus kinase inhibitor", 
      "background MTX", 
      "tofacitinib doses", 
      "radiographic efficacy", 
      "responder patients", 
      "MTX dose", 
      "efficacy endpoint", 
      "methotrexate dose", 
      "Sharp score", 
      "activity score", 
      "dose group", 
      "placebo", 
      "American College", 
      "patients", 
      "structural progression", 
      "tofacitinib", 
      "ORAL Scan", 
      "activity index", 
      "doses", 
      "kinase inhibitors", 
      "arthritis", 
      "efficacy", 
      "MTX", 
      "dose", 
      "baseline", 
      "scores", 
      "DAS28", 
      "trials", 
      "progression", 
      "endpoint", 
      "index", 
      "scans", 
      "treatment", 
      "inhibitors", 
      "rate", 
      "improvement", 
      "group", 
      "changes", 
      "joints", 
      "College", 
      "post", 
      "effect", 
      "bid", 
      "categories", 
      "analysis", 
      "high (\u226517.5\u00a0mg/week) stable background MTX", 
      "stable background MTX", 
      "Assessment Questionnaire-Disability Index", 
      "Questionnaire-Disability Index", 
      "MTX category", 
      "less structural progression", 
      "background methotrexate dose group", 
      "methotrexate dose group"
    ], 
    "name": "Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group", 
    "pagination": "15-24", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1011836710"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10067-016-3436-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27734232"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10067-016-3436-1", 
      "https://app.dimensions.ai/details/publication/pub.1011836710"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_694.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10067-016-3436-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10067-016-3436-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10067-016-3436-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10067-016-3436-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10067-016-3436-1'


 

This table displays all metadata directly associated to this object as RDF triples.

278 TRIPLES      21 PREDICATES      118 URIs      110 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10067-016-3436-1 schema:about N0fe2113464874f06b0a12bc345005f39
2 N0fe9ed519e4f47b3b63328bf92048ec1
3 N151e6fa1afe84fef919606804e0a037a
4 N20524d1886a94b7d83bda3de9e668eb9
5 N4c061b43ac084ca28ef39103399b56dc
6 N7b12398bb3074fc7ab4a5e24c7bd79d0
7 N82f561039a72477abf32950339ce7538
8 N83f918fd82424b6488a4c4b1417043c2
9 N8cea84f3d1a349c9833d070d244e1fd5
10 N9007098440634e39977983d243ebf8ad
11 N969dabd4d4e2445bb7c2cc123dda6746
12 N98629133db4c496eb0678727d5fa9342
13 N9ddb8413707746df85bd5871ca003c70
14 Na646b0474c904fbea9b82a41d62f5c7c
15 Nb4371d1b287f4159a34d76bd2e14f36c
16 Nbc7873933ea84d44a9efc79dee15bb82
17 Nc3f3a6fcd9284703b0facc0c3c7a7239
18 Ne6045bb8f7e841ae957201c306bed141
19 Nef80612e3ef747febf152b318f0cd8c9
20 Nfd455393ddbc476d9864db5d05ebda3d
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author N1eb34b449d944bfb9ec6dbd8968509de
24 schema:datePublished 2016-10-12
25 schema:datePublishedReg 2016-10-12
26 schema:description Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis investigated the effect of methotrexate (MTX) dose on the efficacy of tofacitinib in patients with RA. ORAL Scan (NCT00847613) was a 2-year, randomized, Phase 3 trial evaluating tofacitinib in MTX-inadequate responder (IR) patients with RA. Patients received tofacitinib 5 or 10 mg twice daily (BID), or placebo, with low (≤12.5 mg/week), moderate (>12.5 to <17.5 mg/week), or high (≥17.5 mg/week) stable background MTX. Efficacy endpoints (at months 3 and 6) included American College of Rheumatology (ACR) 20/50/70 response rates, and mean change from baseline in Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 joints (DAS28)-4(erythrocyte sedimentation rate [ESR]), Health Assessment Questionnaire-Disability Index (HAQ-DI), and modified Total Sharp score. 797 patients were treated with tofacitinib 5 mg BID (N = 321), tofacitinib 10 mg BID (N = 316), or placebo (N = 160); 242, 333, and 222 patients received low, moderate, and high MTX doses, respectively. At months 3 and 6, ACR20/50/70 response rates were greater for both tofacitinib doses vs placebo across all MTX doses. At month 3, mean changes from baseline in CDAI and HAQ-DI were significantly greater for both tofacitinib doses vs placebo, irrespective of MTX category; improvements were maintained at month 6. Both tofacitinib doses demonstrated improvements in DAS28-4(ESR), and less structural progression vs placebo, across MTX doses at month 6. Tofacitinib plus MTX showed greater clinical and radiographic efficacy than placebo in MTX-IR patients with RA, regardless of MTX dose.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf N044a8a781dbb41eabdc77dbb5595bd00
31 N77b25b9f3a9348f5a3fb48595c0723c3
32 sg:journal.1093299
33 schema:keywords ACR20/50/70 response rates
34 American College
35 Assessment Questionnaire-Disability Index
36 Clinical Disease Activity Index
37 College
38 DAS28
39 Disease Activity Index
40 Disease Activity Score
41 Health Assessment Questionnaire Disability Index
42 Janus kinase inhibitor
43 MTX
44 MTX category
45 MTX dose
46 MTX doses
47 MTX-IR patients
48 MTX-inadequate responder patients
49 ORAL Scan
50 Questionnaire-Disability Index
51 Rheumatology (ACR) 20/50/70 response rates
52 Sharp score
53 activity index
54 activity score
55 analysis
56 arthritis
57 background MTX
58 background methotrexate dose group
59 baseline
60 bid
61 categories
62 changes
63 dose
64 dose group
65 doses
66 effect
67 efficacy
68 efficacy endpoint
69 efficacy of tofacitinib
70 endpoint
71 group
72 high (≥17.5 mg/week) stable background MTX
73 higher MTX doses
74 improvement
75 index
76 inhibitors
77 joints
78 kinase inhibitors
79 less structural progression
80 methotrexate dose
81 methotrexate dose group
82 month 3
83 month 6
84 oral Janus kinase inhibitor
85 patients
86 phase 3 trial
87 placebo
88 post
89 progression
90 radiographic efficacy
91 rate
92 responder patients
93 response rate
94 rheumatoid arthritis
95 scans
96 scores
97 stable background MTX
98 structural progression
99 tofacitinib
100 tofacitinib 5
101 tofacitinib doses
102 total Sharp score
103 treatment
104 trials
105 schema:name Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
106 schema:pagination 15-24
107 schema:productId N9d37ca4d84f042fb947067b00228b1f6
108 Nbb370fed3bae4a2780656f5469e091a7
109 Nf85ed3f66dd7434ebcbdc57d35d85ba1
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011836710
111 https://doi.org/10.1007/s10067-016-3436-1
112 schema:sdDatePublished 2021-12-01T19:36
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher N9a6e3e45e1764d7e880b4ad4f16542d2
115 schema:url https://doi.org/10.1007/s10067-016-3436-1
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N044a8a781dbb41eabdc77dbb5595bd00 schema:issueNumber 1
120 rdf:type schema:PublicationIssue
121 N0e45003c061e425bbd7ab2fa9aaa691f rdf:first sg:person.01073167753.60
122 rdf:rest rdf:nil
123 N0fe2113464874f06b0a12bc345005f39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Adult
125 rdf:type schema:DefinedTerm
126 N0fe9ed519e4f47b3b63328bf92048ec1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Drug Therapy, Combination
128 rdf:type schema:DefinedTerm
129 N151e6fa1afe84fef919606804e0a037a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Pyrroles
131 rdf:type schema:DefinedTerm
132 N1eb34b449d944bfb9ec6dbd8968509de rdf:first sg:person.01065106031.43
133 rdf:rest N63ac9bf14e5947e08251545d96d105b3
134 N20524d1886a94b7d83bda3de9e668eb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Surveys and Questionnaires
136 rdf:type schema:DefinedTerm
137 N4c061b43ac084ca28ef39103399b56dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Piperidines
139 rdf:type schema:DefinedTerm
140 N63ac9bf14e5947e08251545d96d105b3 rdf:first sg:person.012234527537.40
141 rdf:rest N7c053a82a2624ca692647754d48abc77
142 N74a6468a070a4b0fa554e426b52ea122 rdf:first sg:person.01323573350.82
143 rdf:rest N93562bc99c6c4000990c055cd8ef5935
144 N77b25b9f3a9348f5a3fb48595c0723c3 schema:volumeNumber 36
145 rdf:type schema:PublicationVolume
146 N7b12398bb3074fc7ab4a5e24c7bd79d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Aged
148 rdf:type schema:DefinedTerm
149 N7c053a82a2624ca692647754d48abc77 rdf:first sg:person.014133305773.18
150 rdf:rest N74a6468a070a4b0fa554e426b52ea122
151 N82f561039a72477abf32950339ce7538 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Middle Aged
153 rdf:type schema:DefinedTerm
154 N83f918fd82424b6488a4c4b1417043c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Blood Sedimentation
156 rdf:type schema:DefinedTerm
157 N8cea84f3d1a349c9833d070d244e1fd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Treatment Outcome
159 rdf:type schema:DefinedTerm
160 N9007098440634e39977983d243ebf8ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Disease Progression
162 rdf:type schema:DefinedTerm
163 N93562bc99c6c4000990c055cd8ef5935 rdf:first sg:person.01011713026.12
164 rdf:rest N9b4df906480549d29d29796a7c910f52
165 N969dabd4d4e2445bb7c2cc123dda6746 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Male
167 rdf:type schema:DefinedTerm
168 N98629133db4c496eb0678727d5fa9342 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Double-Blind Method
170 rdf:type schema:DefinedTerm
171 N9a6e3e45e1764d7e880b4ad4f16542d2 schema:name Springer Nature - SN SciGraph project
172 rdf:type schema:Organization
173 N9b4df906480549d29d29796a7c910f52 rdf:first sg:person.0614545245.28
174 rdf:rest Nc5c18fa633054bf68b6bcd60c66dca48
175 N9d37ca4d84f042fb947067b00228b1f6 schema:name pubmed_id
176 schema:value 27734232
177 rdf:type schema:PropertyValue
178 N9ddb8413707746df85bd5871ca003c70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Janus Kinases
180 rdf:type schema:DefinedTerm
181 Na646b0474c904fbea9b82a41d62f5c7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Humans
183 rdf:type schema:DefinedTerm
184 Nb4371d1b287f4159a34d76bd2e14f36c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Regression Analysis
186 rdf:type schema:DefinedTerm
187 Nbb370fed3bae4a2780656f5469e091a7 schema:name doi
188 schema:value 10.1007/s10067-016-3436-1
189 rdf:type schema:PropertyValue
190 Nbc7873933ea84d44a9efc79dee15bb82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Pyrimidines
192 rdf:type schema:DefinedTerm
193 Nc3f3a6fcd9284703b0facc0c3c7a7239 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Female
195 rdf:type schema:DefinedTerm
196 Nc5c18fa633054bf68b6bcd60c66dca48 rdf:first sg:person.011262137261.94
197 rdf:rest N0e45003c061e425bbd7ab2fa9aaa691f
198 Ne6045bb8f7e841ae957201c306bed141 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Arthritis, Rheumatoid
200 rdf:type schema:DefinedTerm
201 Nef80612e3ef747febf152b318f0cd8c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Antirheumatic Agents
203 rdf:type schema:DefinedTerm
204 Nf85ed3f66dd7434ebcbdc57d35d85ba1 schema:name dimensions_id
205 schema:value pub.1011836710
206 rdf:type schema:PropertyValue
207 Nfd455393ddbc476d9864db5d05ebda3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Methotrexate
209 rdf:type schema:DefinedTerm
210 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
211 schema:name Medical and Health Sciences
212 rdf:type schema:DefinedTerm
213 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
214 schema:name Clinical Sciences
215 rdf:type schema:DefinedTerm
216 sg:journal.1093299 schema:issn 0770-3198
217 1434-9949
218 schema:name Clinical Rheumatology
219 schema:publisher Springer Nature
220 rdf:type schema:Periodical
221 sg:person.01011713026.12 schema:affiliation grid-institutes:grid.410513.2
222 schema:familyName Soma
223 schema:givenName K
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011713026.12
225 rdf:type schema:Person
226 sg:person.01065106031.43 schema:affiliation grid-institutes:grid.267313.2
227 schema:familyName Fleischmann
228 schema:givenName R
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065106031.43
230 rdf:type schema:Person
231 sg:person.01073167753.60 schema:affiliation grid-institutes:grid.410513.2
232 schema:familyName Bananis
233 schema:givenName E
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073167753.60
235 rdf:type schema:Person
236 sg:person.011262137261.94 schema:affiliation grid-institutes:grid.410513.2
237 schema:familyName Takiya
238 schema:givenName L
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011262137261.94
240 rdf:type schema:Person
241 sg:person.012234527537.40 schema:affiliation grid-institutes:grid.34477.33
242 schema:familyName Mease
243 schema:givenName P J
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012234527537.40
245 rdf:type schema:Person
246 sg:person.01323573350.82 schema:affiliation grid-institutes:grid.410513.2
247 schema:familyName Hwang
248 schema:givenName L-J
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323573350.82
250 rdf:type schema:Person
251 sg:person.014133305773.18 schema:affiliation grid-institutes:grid.239915.5
252 schema:familyName Schwartzman
253 schema:givenName S
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18
255 rdf:type schema:Person
256 sg:person.0614545245.28 schema:affiliation grid-institutes:grid.410513.2
257 schema:familyName Connell
258 schema:givenName C A
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614545245.28
260 rdf:type schema:Person
261 grid-institutes:grid.239915.5 schema:alternateName Hospital for Special Surgery, New York, NY, USA.
262 schema:name Hospital for Special Surgery, New York, NY, USA.
263 rdf:type schema:Organization
264 grid-institutes:grid.267313.2 schema:alternateName Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA.
265 schema:name Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA.
266 rdf:type schema:Organization
267 grid-institutes:grid.34477.33 schema:alternateName Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA.
268 schema:name Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA.
269 rdf:type schema:Organization
270 grid-institutes:grid.410513.2 schema:alternateName Pfizer Inc, Collegeville, PA, USA.
271 Pfizer Inc, Collegeville, PA, USA. stratis.bananis@pfizer.com.
272 Pfizer Inc, Groton, CT, USA.
273 Pfizer Inc, New York, NY, USA.
274 schema:name Pfizer Inc, Collegeville, PA, USA.
275 Pfizer Inc, Collegeville, PA, USA. stratis.bananis@pfizer.com.
276 Pfizer Inc, Groton, CT, USA.
277 Pfizer Inc, New York, NY, USA.
278 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...